Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2023 16:00 ET | Source: Dyadic International, Inc.

Dyadic Reports 2022 Year End Results and Recent Company Progress

Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding...
March 15, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023

JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
March 07, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 ...
March 01, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic to Present at Roth Investor Conference and Upcoming Industry Events

JUPITER, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
February 02, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic to Participate in Two Upcoming Investor Conferences

JUPITER, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
January 24, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
January 19, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic Announces Sale of Equity Interest in Alphazyme

JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
January 04, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference

JUPITER, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
December 14, 2022 08:30 ET | Source: Dyadic International, Inc.

Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal

“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...
November 10, 2022 16:00 ET | Source: Dyadic International, Inc.

Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments

Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for...